Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Revenue (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Revenue data on record, last reported at $151.7 million in Q4 2025.

  • For Q4 2025, Revenue rose 128.39% year-over-year to $151.7 million; the TTM value through Dec 2025 reached $451.4 million, up 146.71%, while the annual FY2025 figure was $451.4 million, 146.71% up from the prior year.
  • Revenue reached $151.7 million in Q4 2025 per TARS's latest filing, up from $118.7 million in the prior quarter.
  • Across five years, Revenue topped out at $151.7 million in Q4 2025 and bottomed at $338000.0 in Q4 2021.
  • Average Revenue over 5 years is $40.8 million, with a median of $24.8 million recorded in 2021.
  • The widest YoY moves for Revenue: up 2858.58% in 2022, down 98.39% in 2022.
  • A 5-year view of Revenue shows it stood at $338000.0 in 2021, then skyrocketed by 2858.58% to $10.0 million in 2022, then skyrocketed by 30.76% to $13.1 million in 2023, then skyrocketed by 407.86% to $66.4 million in 2024, then surged by 128.39% to $151.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $151.7 million in Q4 2025, $118.7 million in Q3 2025, and $102.7 million in Q2 2025.